secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0000950170-23-051276
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS sets Medicare price for Renalytix's kidneyintelX.dkd test at $950, effective Jan 2024
--------------------------------------------------------------------------------

- CMS published price for FDA-authorized kidneyintelX.dkd test on national Clinical Lab Fee Schedule at $950.
- Pricing effective Jan 1, 2024 and maintained for a minimum of three years.
- AMA panel recommended a new CPT code to differentiate kidneyintelX.dkd from the original LDT, triggering the pricing review.
- Company states the CMS action affirms KidneyIntelX platform value and aids in expanding insurance coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017023051276/0000950170-23-051276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017023051276/rnlx-20231003.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer